Sixteen dogs with generalized demodicosis were treated with either Bravecto or AdvocateŽ (Advantage MultiŽ in the US). Bravecto was administered once orally at a minimum dose of 25 mg fluralaner/kg), while Advocate was administered topically three times at 4 week intervals. Skin scraping mite counts and skin lesions were monitored monthly by a blinded investigator.

Mite numbers were reduced by 99.8% on Day 28, and 100% on Days 56 and 84 after a single dose of Bravecto. In the Advocate treated dogs, mite numbers were reduced by 98% on Day 28, 96.5% on Day 56, and 94.7% on Day 84. Skin lesions improved in both treatment groups.

This small study provides evidence for the efficacy of Bravecto for the off-label treatment of generalized demodicosis in dogs. Our experience at SkinVet Clinic supports these findings, with some dramatic responses seen so far. Presumably, we can also prevent relapses in predisposed dogs.